CO2021003726A2 - Métodos para reducir el riesgo de diabetes en pacientes que se tratan por enfermedades relacionadas con colesterol alto - Google Patents
Métodos para reducir el riesgo de diabetes en pacientes que se tratan por enfermedades relacionadas con colesterol altoInfo
- Publication number
- CO2021003726A2 CO2021003726A2 CONC2021/0003726A CO2021003726A CO2021003726A2 CO 2021003726 A2 CO2021003726 A2 CO 2021003726A2 CO 2021003726 A CO2021003726 A CO 2021003726A CO 2021003726 A2 CO2021003726 A2 CO 2021003726A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- diabetes
- patients
- statin
- risk
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 2
- 235000012000 cholesterol Nutrition 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 4
- HYHMLYSLQUKXKP-UHFFFAOYSA-N bempedoic acid Chemical compound OC(=O)C(C)(C)CCCCCC(O)CCCCCC(C)(C)C(O)=O HYHMLYSLQUKXKP-UHFFFAOYSA-N 0.000 abstract 3
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 abstract 3
- 229960000815 ezetimibe Drugs 0.000 abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862722766P | 2018-08-24 | 2018-08-24 | |
| US201862751404P | 2018-10-26 | 2018-10-26 | |
| PCT/US2019/048184 WO2020041799A1 (en) | 2018-08-24 | 2019-08-26 | Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021003726A2 true CO2021003726A2 (es) | 2021-07-30 |
Family
ID=69591419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0003726A CO2021003726A2 (es) | 2018-08-24 | 2021-03-24 | Métodos para reducir el riesgo de diabetes en pacientes que se tratan por enfermedades relacionadas con colesterol alto |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210322376A1 (https=) |
| EP (1) | EP3841105A4 (https=) |
| JP (2) | JP2021534208A (https=) |
| KR (1) | KR20210079275A (https=) |
| CN (1) | CN113166195A (https=) |
| AU (1) | AU2019325705A1 (https=) |
| BR (1) | BR112021003265A2 (https=) |
| CA (1) | CA3110346A1 (https=) |
| CL (1) | CL2021000444A1 (https=) |
| CO (1) | CO2021003726A2 (https=) |
| IL (1) | IL281016A (https=) |
| MX (1) | MX2021002090A (https=) |
| PH (1) | PH12021550656A1 (https=) |
| SG (1) | SG11202101717WA (https=) |
| WO (1) | WO2020041799A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3267989A4 (en) | 2015-03-13 | 2018-11-07 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
| US20210322375A1 (en) * | 2018-08-27 | 2021-10-21 | Esperion Therapeutics, Inc. | Combination drug formulations for treating patients with cardiovascular disease and associated conditions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2008000684A1 (es) * | 2007-03-09 | 2008-08-01 | Indigene Pharmaceuticals Inc | Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica. |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| CN103239449A (zh) * | 2012-12-26 | 2013-08-14 | 辽宁亿灵科创生物医药科技有限公司 | 一种依折麦布、辛伐他汀和烟酸的复方制剂及其制备方法 |
| MA41793A (fr) * | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| WO2018148417A1 (en) * | 2017-02-08 | 2018-08-16 | Esperion Therapeutics, Inc. | Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease |
-
2019
- 2019-08-26 MX MX2021002090A patent/MX2021002090A/es unknown
- 2019-08-26 EP EP19852458.9A patent/EP3841105A4/en active Pending
- 2019-08-26 JP JP2021510013A patent/JP2021534208A/ja active Pending
- 2019-08-26 US US17/271,045 patent/US20210322376A1/en active Pending
- 2019-08-26 SG SG11202101717WA patent/SG11202101717WA/en unknown
- 2019-08-26 KR KR1020217008742A patent/KR20210079275A/ko not_active Ceased
- 2019-08-26 CA CA3110346A patent/CA3110346A1/en active Pending
- 2019-08-26 PH PH1/2021/550656A patent/PH12021550656A1/en unknown
- 2019-08-26 WO PCT/US2019/048184 patent/WO2020041799A1/en not_active Ceased
- 2019-08-26 BR BR112021003265-7A patent/BR112021003265A2/pt unknown
- 2019-08-26 AU AU2019325705A patent/AU2019325705A1/en not_active Abandoned
- 2019-08-26 CN CN201980067823.7A patent/CN113166195A/zh active Pending
-
2021
- 2021-02-22 CL CL2021000444A patent/CL2021000444A1/es unknown
- 2021-02-22 IL IL281016A patent/IL281016A/en unknown
- 2021-03-24 CO CONC2021/0003726A patent/CO2021003726A2/es unknown
-
2024
- 2024-03-05 JP JP2024032974A patent/JP2024081650A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11202101717WA (en) | 2021-03-30 |
| CN113166195A (zh) | 2021-07-23 |
| CL2021000444A1 (es) | 2021-07-02 |
| MX2021002090A (es) | 2021-04-28 |
| WO2020041799A1 (en) | 2020-02-27 |
| KR20210079275A (ko) | 2021-06-29 |
| BR112021003265A2 (pt) | 2021-05-18 |
| PH12021550656A1 (en) | 2022-03-14 |
| EP3841105A1 (en) | 2021-06-30 |
| JP2024081650A (ja) | 2024-06-18 |
| US20210322376A1 (en) | 2021-10-21 |
| IL281016A (en) | 2021-04-29 |
| JP2021534208A (ja) | 2021-12-09 |
| EP3841105A4 (en) | 2022-05-04 |
| AU2019325705A1 (en) | 2021-03-18 |
| CA3110346A1 (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020009246A (es) | Uso del inhibidor de pcsk9 para disminuir el riesgo cardiovascular. | |
| MX2017000628A (es) | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. | |
| MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
| CO2022004902A2 (es) | Anticuerpo anti beta-amiloide para el tratamiento de la enfermedad de alzheimer | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2016011975A (es) | Metodos para reducir el riesgo cardiovascular. | |
| MX2022001841A (es) | Anticuerpos contra ilt2 y uso de los mismos. | |
| MX2023003942A (es) | Metodos para el tratamiento del asma en sujetos pediatricos mediante la administracion de un antagonista del il-4r. | |
| EA201170669A1 (ru) | Лечение пирфенидоном пациентов с атипичной функцией печени | |
| EA201890891A1 (ru) | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| UA122331C2 (uk) | Антитіло проти flt3 та кон'югат антитіло-лікарський засіб (adc), який зв'язується з білком flt3 | |
| EA201590655A1 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| EA202191165A1 (ru) | Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы | |
| BR112022007721A2 (pt) | Método para o tratamento da demência | |
| RU2016117729A (ru) | Терапия рака путем таргетинга покоящихся раковых клеток | |
| MX2020006284A (es) | Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson. | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| CO2021003726A2 (es) | Métodos para reducir el riesgo de diabetes en pacientes que se tratan por enfermedades relacionadas con colesterol alto | |
| CO2017008395A2 (es) | Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| MX2022003610A (es) | Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
| EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
| CO2021014370A2 (es) | Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen |